To Allay Customers’ New Apprehensions Pharma Needs A New Conversation

Since the beginning of 2020, witnessing the rapid spread of Covid pandemic with very high global fatality rate – virtually the entire global populations – directly or indirectly, have been looking up to the health care industry for help. This, … Continue reading

Shape of Future Pharma Operations – Emerging A Pragmatic Outlook?

Just as newer reports come almost every day on safety, efficacy, dosage interval or span of immunity of Covid vaccines, similar reports are also reaching us about the possible future shape of pharma sales and marketing operations. Some hardcore optimists, … Continue reading

Still Evolving: Pharma’s New Pathway For Digital And F2F Customer Engagement

Last year – probably left with no better choice – the pharma industry, in general, had to take an unprecedented interest in digitalization of business processes. It happened faster than ever, especially in the marketing domain, along with a few … Continue reading

Covid Prompts Pharma To Move Away From Competition Driven Business Model

As deliberated in my just previous article in this blog, Covid has been a watershed in several areas of pharma business. One such key area is its competition driven strategic business model. It aims to deliver significant value for a … Continue reading

Pharma Sales Post Covid-19 Lockdown

Disruptions from Covid-19 pandemic have caused limited access to physicians for Pfizer’s marketing and sales teams have had. If ‘the novel Coronavirus pandemic hamstringing the company’s sales team,’ there could be a slowdown in new prescriptions and a sales hit in the second quarter, said the global … Continue reading

Any Threat To Current Commercial Model Of ‘Gene Therapy’?

Wish All My Readers A Very Happy, Healthy, Peaceful and Prosperous 2020   One of the most complex areas in disease management, is the ailments related to genetic disorders. As these were incurable, over the last four decades, medical researchers … Continue reading

Drug Pricing: Why Justify On R&D Cost Rather Than Precise ‘Customer Value’?

While looking around, it won’t be difficult to spot many types of steep-priced highly innovative products, where high costs aren’t justified by high R&D expenditure, but for unique ‘customer value’ offerings. Many consumers evaluate those and decide to settle for … Continue reading

Adopt A Hybrid Business Model For Better Sales – Not A Large Field Force

For aggressive business expansion or to attain greater market access, creating a large sales force has been the thumb rule in the pharma industry, since long. To meet the challenge of changing market dynamics, going for a thorough re-engineering of … Continue reading